News and analysis on disease research and diagnostics.
MyCartis said that the new company, Antelope Dx, is developing a home test to diagnose Chlamydia trachomatis and Neisseria gonorrhea.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
The firm provided updates on its bacterial pathogen detection and antimicrobial resistance testing for bacterial isolates and a direct-from-urine test.
The system is designed to analyze data from routine blood and biochemistry tests to identify immunological abnormalities that indicate high cancer risk.
